Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22013154 | 0.77 | NTRK1 (0.33) | NTRK1JAK2 | |
| SCHEMBL24200659 | 0.73 | NTRK1 (0.43) | NTRK1JAK2 | |
| SCHEMBL24200637 | 0.66 | NTRK1 (0.38) | NTRK1JAK2 | |
| SCHEMBL24200521 | 0.66 | NTRK1 (0.34) | NTRK1JAK2 | |
| SCHEMBL24200666 | 0.66 | NTRK1 (0.37) | NTRK1JAK2 | |
| SCHEMBL24200681 | 0.65 | NTRK1 (0.40) | NTRK1JAK2 | |
| SCHEMBL24200729 | 0.64 | NTRK1 (0.36) | NTRK1JAK2 | |
| SCHEMBL24200630 | 0.63 | NTRK1 (0.52) | NTRK1JAK2 | |
| SCHEMBL22013130 | 0.63 | NTRK1 (0.39) | NTRK1JAK2 | |
| SCHEMBL28605193 | 0.63 | NTRK1 (0.39) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017512-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, ERBB2, ERBB3 | NTRK1 40/4885JAK2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.